The DYRK family of kinases in cancer: molecular functions and therapeutic opportunities

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Boni, Jacopo, 1987-
• dc.contributor.author Rubio Pérez, Carlota, 1990-
• dc.contributor.author López Bigas, Núria
• dc.contributor.author Fillat i Fonts, Cristina
• dc.contributor.author Luna, Susana de la
• dc.date.accessioned 2020-10-19T07:02:08Z
• dc.date.available 2020-10-19T07:02:08Z
• dc.date.issued 2020
• dc.description.abstract DYRK (dual-specificity tyrosine-regulated kinases) are an evolutionary conserved family of protein kinases with members from yeast to humans. In humans, DYRKs are pleiotropic factors that phosphorylate a broad set of proteins involved in many different cellular processes. These include factors that have been associated with all the hallmarks of cancer, from genomic instability to increased proliferation and resistance, programmed cell death, or signaling pathways whose dysfunction is relevant to tumor onset and progression. In accordance with an involvement of DYRK kinases in the regulation of tumorigenic processes, an increasing number of research studies have been published in recent years showing either alterations of DYRK gene expression in tumor samples and/or providing evidence of DYRK-dependent mechanisms that contribute to tumor initiation and/or progression. In the present article, we will review the current understanding of the role of DYRK family members in cancer initiation and progression, providing an overview of the small molecules that act as DYRK inhibitors and discussing the clinical implications and therapeutic opportunities currently available.
• dc.description.sponsorship J.B. is an FPI predoctoral fellow (BES-2014-069983). De la Luna’s lab is supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-76141-P, AEI/FEDER), the AGAUR grant from Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya (SGR14/674) and the CIBER de Enfermedades Raras. We thank La Marato of TV3 for its support to our research in cancer. We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the support of the CERCA Programme/Generalitat de Catalunya.
• dc.format.mimetype application/pdf
• dc.identifier.citation Boni J, Rubio-Perez C, López-Bigas N, Fillat C, de la Luna S. The DYRK family of kinases in cancer: molecular functions and therapeutic opportunities. Cancers (Basel). 2020; 12(8):2106. DOI: 10.3390/cancers12082106
• dc.identifier.doi http://dx.doi.org/10.3390/cancers12082106
• dc.identifier.issn 2072-6694
• dc.identifier.uri http://hdl.handle.net/10230/45502
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Cancers (Basel). 2020; 12(8):2106
• dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/BFU2016-76141-P
• dc.rights © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword DYRK kinases
• dc.subject.keyword Cell cycle
• dc.subject.keyword Cell survival
• dc.subject.keyword Cellular signaling
• dc.subject.keyword Expression dysregulation
• dc.subject.keyword Kinase inhibitors
• dc.subject.keyword Tumor progression
• dc.title The DYRK family of kinases in cancer: molecular functions and therapeutic opportunities
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion